Financing round D for 20 CHF was closed - Phase II clinical trial successfully initiated - Focus of the report: InflammAging
MetrioPharm AG, a pharmaceutical development company, publishes its annual report for 2018.
Dr. Wolfgang Brysch, CEO of MetrioPharm AG: "In the past fiscal year, we were able to decisively advance the development of our lead compound MP1032. In April, the Phase II clinical trial for the indication psoriasis started. Patient recruitment has now been completed to our satisfaction.
Patient acceptance is an important signal for us, it confirms us in expanding our development strategy: From autoimmune diseases to the constantly growing field of age-related chronic inflammatory diseases (InflammAging). The need for well-tolerated and safe therapies is still almost unmet.
With the 20 million CHF from the current financing round, we will be able to effectively drive this strategy forward."
For an introduction to the main topic of the annual report InflammAging, please visit the MetrioPharm Blog.